Treatment preferences of patients with crohn’s disease: Development of the IMPLICA questionnaire

Revista Espanola de Enfermedades Digestivas

Volumn 106, Issue 6, 2014, Pages 372-380

  Borruel, Natalia ^a   Castro, Javier ^b   Riestra, Sabino ^c   Costi, María ^d   Casellas, Francesc ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Universidad de La Coruña   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d ABBVIE INC   (United States)

Author keywords

Biological therapy; Crohn s disease; Preferences

Indexed keywords

ARTICLE; BIOLOGICAL THERAPY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CROHN DISEASE; DISEASE CONTROL; DRUG ADMINISTRATION ROUTE; HEALTH CARE QUALITY; HUMAN; IMPLICA QUESTIONNAIRE; PATIENT PREFERENCE; PLACE PREFERENCE; QUALITATIVE RESEARCH; QUESTIONNAIRE; TREATMENT DURATION; PATIENT SATISFACTION;

BIOLOGICAL PRODUCT;

BIOLOGICAL PRODUCTS; CROHN DISEASE; HUMANS; PATIENT SATISFACTION; SURVEYS AND QUESTIONNAIRES;

EID: 84927626947     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Saro C, Riestra Menéndez S, Milla Crespo A, Sánchez Fernández R, Lacort Fernández M, Argüelles Fernández G, et al. Incidencia y prevalencia en enfermedad inflamatoria intestinal crónica. Estudio asturiano en cinco áreas. An Med Interna 2003;20:3-9.
2. Faegan BG, Panaccione R, Sandborn WJ, D’Haens GR, Schereiber S, Rutgeerts PJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology 2008;135:1493-9.
3. Taxonera C, Rodrigo L, Casellas F, Calvet X, Gómez-Camacho F, Ginard D, et al. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn’s disease. J Clin Gastroenterol 2009;43:950-6.
4. Casellas F, Arenas JI, Baudet JS, Fabregas S, Garcia N, Gelabert J, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: A Spanish multicenter study. Inflamm Bowel Dis 2005;11:488-96.
5. Casellas F, Robles V, Borruel N, Torrejón A, Castells I, Navarro E, et al. Restoration of quality of life of patiens with inflammatory bowel disease after one year with antiTNFα treatment. J Crohn’s Colitis 2012;6:881-6.
6. Travis S, Van Assche G, Diagnass A, Cabré E, Gassull MA. On the second ECCO consensus on Crohn’s disease. J Crohns Colitis 2010;4:1-6.
7. Esser D, Cornillie F, Diamond RH, Spiegel RJ. On the updated ECCO consensus guidelines for medical management of Crohn’s disease. J Crohns Colitis 2011;5:165-6.
8. Bears JE, Markus T, Kuipers EJ, van der Woude CJ. Patients’ preferences regarding shared decision-making in the treatment of inflammatory bowel disease: Results from a patient empowerment study. Digestion 2010;81:113-9.
9. Siegel CA. Making therapeutic decisions in inflammatory bowel disease: The role of patients. Curr Opin Gastroenterol 2009;25: 334-8.
10. Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence 2009;3:335-44.
11. Duarte JW, Bolge SC, Sen SS. An evaluation of patients’ preferences for osteoporosis medications and their attributes: The PREFER-International study. Clin Ther 2007;29:488-503.
12. Plantinga LC, Fink NE, Bass EB, Boulware LE, Meyer KB, Powe NR. Preferences for current health and their association with outcomes in patients with kidney disease. Med Care 2007;45:230-7.
13. Van Houtven G, Johnson FR, Kilambi V, Hauber AB. Eliciting benefitrisk preferences and probability-weighted utility using choice-format conjoint analysis. Med Decis Making 2011;31:469-80.
14. Siegel CA. Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis 2010;16:2168-72.
15. Johnson FR, Hauber B, Özdemir S, Siegel CA, Hass S, Sands BE. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn’s disease management. J Manag Care Pharm 2010;16:616-28.
16. Allen PB, Lindsay H, Tham TC. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol 2010;10:1.
17. Green PE and Srinivasan V. Conjoint Analysis in Marketing: New Developments with Implications for Research and Practice. J Marketing 1990;54:3-19.
18. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000;320:1530-3.
19. Bridges J, Kinter E, Kidane L, Heinzen RR, McCormick C. Things are looking up since we started listening to patients. Trends in the application of conjoint analysis in health 1982-2007. Patient. 2008; 1(4):273-82.
20. Home page on the Internet]. http://support.spss.com/ProductsExt/SPSS/ESD/17/Download/User%20Manuals/English/SPSS%20Conjoint% 2017.0.pdf
21. Sánchez N, Salamero M, Sirgo A, Hollenstein MF, León C, Lacorte TM. Preferencias de comunicación y apoyo de pacientes oncológicos españoles. Adaptación del “measure of patient’s preferences”. Psicooncología 2005;2:81-90.
22. Zachariae R, Pedersen CG, Jensen AB, Ehrnrooth E, Rossen PB, von der Maase H. Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease. Br J Cancer 2003; 88:658-65.
23. Deber RB. Shared decision making in the real world. J Gen Intern Med 1996;11:377-8.
24. Van Houtven G, Johson FR, Kilabmi V, Hauber AB. Eliciting benefitrisk preferences and probability weighted utility using choice-format conjoint analysis. Med Decis Making 2011;31:469-80.
25. Ryan M. A role for conjoint analysis in technology assessment in health care? Int J Technol Assess Health Care 1999;15:443-57.